Community Bank of Raymore raised its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 24.3% in the third quarter, Holdings Channel.com reports. The fund owned 7,805 shares of the biopharmaceutical company’s stock after acquiring an additional 1,525 shares during the quarter. Community Bank of Raymore’s holdings in Bristol-Myers Squibb were worth $395,000 at the end of the most recent reporting period.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Several other institutional investors have also recently made changes to their positions in the business. First Personal Financial Services increased its holdings in shares of Bristol-Myers Squibb by 7.7% in the third quarter. First Personal Financial Services now owns 2,831 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 202 shares during the last quarter. Thomasville National Bank grew its position in Bristol-Myers Squibb by 1.1% in the third quarter. Thomasville National Bank now owns 18,815 shares of the biopharmaceutical company’s stock worth $954,000 after acquiring an additional 210 shares during the period. Taylor Cottrill Erickson & Associates Inc. grew its position in Bristol-Myers Squibb by 2.4% in the third quarter. Taylor Cottrill Erickson & Associates Inc. now owns 9,555 shares of the biopharmaceutical company’s stock worth $485,000 after acquiring an additional 220 shares during the period. Rehmann Capital Advisory Group grew its position in Bristol-Myers Squibb by 2.2% in the second quarter. Rehmann Capital Advisory Group now owns 10,209 shares of the biopharmaceutical company’s stock worth $463,000 after acquiring an additional 224 shares during the period. Finally, Sunbelt Securities Inc. grew its position in Bristol-Myers Squibb by 4.4% in the second quarter. Sunbelt Securities Inc. now owns 5,830 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 246 shares during the period. 80.40% of the stock is owned by institutional investors and hedge funds.
In other news, SVP John E. Elicker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the transaction, the senior vice president now directly owns 74,471 shares in the company, valued at $4,219,526.86. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Louis S. Schmukler sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the transaction, the insider now owns 31,963 shares of the company’s stock, valued at $1,807,827.28. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.
Several brokerages recently weighed in on BMY. UBS Group increased their price objective on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 23rd. Wolfe Research set a $66.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, November 1st. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. Peel Hunt reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, October 29th. Finally, Bank of America began coverage on Bristol-Myers Squibb in a research report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company. Bristol-Myers Squibb has an average rating of “Buy” and a consensus price target of $56.64.
BMY opened at $58.02 on Friday. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $58.46. The business has a fifty day simple moving average of $52.90 and a 200-day simple moving average of $48.19. The firm has a market cap of $91.88 billion, a P/E ratio of 14.58, a P/E/G ratio of 1.31 and a beta of 0.71. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business had revenue of $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. During the same period last year, the business posted $1.09 earnings per share. The company’s quarterly revenue was up 5.6% on a year-over-year basis. Sell-side analysts expect that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were given a dividend of $0.41 per share. The ex-dividend date was Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 2.83%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Trading Penny Stocks
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).